China's drug regulator accepted Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical's clinical trial application for its GenSci144 tablets for chronic kidney disease, according to a Tuesday filing with the Shenzhen bourse.
Related Articles
Asia
Divgi TorqTransfer Systems to Incorporate US Wholly-Owned Subsidiary; Shares Jump 7%
Divgi TorqTransfer Systems (NSE:DIVGIITTS, BOM:543812) said its board has approved the incorporation of a wholly-owned subsidiary in the United States, according to an Indian bourse filing on Monday.Shares of the company jumped over 7% in Tuesday's trade.The company will invest up to 30 million Indian rupees in one or more tranches through equity or other share instruments to support the subsidiary's capital requirements and working capital needs, the filing said.The U.S.-based unit will undertake business development, marketing, promotion, sales, and distribution activities, according to the company filing.
$BOM:543812$NSE:DIVGIITTS
Asia
Meorient Commerce Exhibition to Subscribe for Shares in StepFun
Zhejiang Meorient Commerce Exhibition (SHE:300795) plans to subscribe for shares in a startup artificial intelligence company for 150 million yuan, according to a Shenzhen bourse filing on Monday.The convention and exhibition services provider's shares dipped 20% at the close of Tuesday's trade.Meorient will acquire a stake in Shanghai Jieyue Xingchen Intelligent Technology, which is also named StepFun.StepFun produces and develops AI-driven model processing tools, language, images and videos.
$SHE:300795
Asia
Marksans Pharma's Consolidated Net Profit Jumps in Fiscal Q4; Shares Jump 7%
Marksans Pharma's (NSE:MARKSANS, BOM:524404) consolidated attributable net profit rose to 1.48 billion Indian rupees in the fiscal fourth quarter ended March 31, from 905.5 million rupees a year ago.Earnings per share climbed to 3.27 rupees from 2.00 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Tuesday.Revenue from operations in fiscal Q4 also increased to 8.56 billion rupees from 7.08 billion rupees a year ago.The company's board recommended a final dividend of 0.90 rupees per equity share of face value of 1 rupee per share for the fiscal year ended March 31.The company's shares were up nearly 7% in recent trade.
$BOM:524404$NSE:MARKSANS